Cargando…

Haloperidol and olanzapine mediate metabolic abnormalities through different molecular pathways

The pathogenesis of antipsychotic-induced disturbances of glucose homeostasis is still unclear. Increased visceral adiposity has been suggested to be a possible mediating mechanism. The aim of this study was to investigate, in an animal model, the differential effects of olanzapine and haloperidol o...

Descripción completa

Detalles Bibliográficos
Autores principales: Mondelli, V, Anacker, C, Vernon, A C, Cattaneo, A, Natesan, S, Modo, M, Dazzan, P, Kapur, S, Pariante, C M
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2013
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3566719/
https://www.ncbi.nlm.nih.gov/pubmed/23321805
http://dx.doi.org/10.1038/tp.2012.138
_version_ 1782258589809770496
author Mondelli, V
Anacker, C
Vernon, A C
Cattaneo, A
Natesan, S
Modo, M
Dazzan, P
Kapur, S
Pariante, C M
author_facet Mondelli, V
Anacker, C
Vernon, A C
Cattaneo, A
Natesan, S
Modo, M
Dazzan, P
Kapur, S
Pariante, C M
author_sort Mondelli, V
collection PubMed
description The pathogenesis of antipsychotic-induced disturbances of glucose homeostasis is still unclear. Increased visceral adiposity has been suggested to be a possible mediating mechanism. The aim of this study was to investigate, in an animal model, the differential effects of olanzapine and haloperidol on visceral fat deposition (using magnetic resonance imaging(MRI)) and on critical nodes of the insulin signaling pathway (liver-protein levels of IRS2 (insulin receptor substrate 2), GSK3α (glycogen synthase kinase-3α), GSK3β, GSK3α-Ser21, GSK3β-Ser9). To this end, we studied male Sprague–Dawley rats treated with vehicle (n=8), haloperidol (2 mg kg(−1) per day, n=8), or olanzapine (10 mg kg(−1)per day, n=8), using osmotic minipumps, for 8 weeks. The haloperidol group showed a higher percentage of visceral fat than both the olanzapine group and the vehicle group, whereas there was no difference between the olanzapine and the vehicle group. In terms of insulin signaling pathway, the olanzapine group showed significantly reduced IRS2 levels, reduced phosphorylation of GSK3α and increased phosphorylation of GSK3β, whereas there was no difference between the haloperidol and the vehicle group. Our data suggest that different molecular pathways mediate the disturbances of glucose homeostasis induced by haloperidol and olanzapine with a direct effect of olanzapine on the insulin molecular pathway, possibly partly explaining the stronger propensity of olanzapine for adverse effects on glucose regulation when compared with haloperidol in clinical settings.
format Online
Article
Text
id pubmed-3566719
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher Nature Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-35667192013-02-08 Haloperidol and olanzapine mediate metabolic abnormalities through different molecular pathways Mondelli, V Anacker, C Vernon, A C Cattaneo, A Natesan, S Modo, M Dazzan, P Kapur, S Pariante, C M Transl Psychiatry Original Article The pathogenesis of antipsychotic-induced disturbances of glucose homeostasis is still unclear. Increased visceral adiposity has been suggested to be a possible mediating mechanism. The aim of this study was to investigate, in an animal model, the differential effects of olanzapine and haloperidol on visceral fat deposition (using magnetic resonance imaging(MRI)) and on critical nodes of the insulin signaling pathway (liver-protein levels of IRS2 (insulin receptor substrate 2), GSK3α (glycogen synthase kinase-3α), GSK3β, GSK3α-Ser21, GSK3β-Ser9). To this end, we studied male Sprague–Dawley rats treated with vehicle (n=8), haloperidol (2 mg kg(−1) per day, n=8), or olanzapine (10 mg kg(−1)per day, n=8), using osmotic minipumps, for 8 weeks. The haloperidol group showed a higher percentage of visceral fat than both the olanzapine group and the vehicle group, whereas there was no difference between the olanzapine and the vehicle group. In terms of insulin signaling pathway, the olanzapine group showed significantly reduced IRS2 levels, reduced phosphorylation of GSK3α and increased phosphorylation of GSK3β, whereas there was no difference between the haloperidol and the vehicle group. Our data suggest that different molecular pathways mediate the disturbances of glucose homeostasis induced by haloperidol and olanzapine with a direct effect of olanzapine on the insulin molecular pathway, possibly partly explaining the stronger propensity of olanzapine for adverse effects on glucose regulation when compared with haloperidol in clinical settings. Nature Publishing Group 2013-01 2013-01-15 /pmc/articles/PMC3566719/ /pubmed/23321805 http://dx.doi.org/10.1038/tp.2012.138 Text en Copyright © 2013 Macmillan Publishers Limited http://creativecommons.org/licenses/by-nc-nd/3.0/ This work is licensed under the Creative Commons Attribution-NonCommercial-No Derivative Works 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-nd/3.0/
spellingShingle Original Article
Mondelli, V
Anacker, C
Vernon, A C
Cattaneo, A
Natesan, S
Modo, M
Dazzan, P
Kapur, S
Pariante, C M
Haloperidol and olanzapine mediate metabolic abnormalities through different molecular pathways
title Haloperidol and olanzapine mediate metabolic abnormalities through different molecular pathways
title_full Haloperidol and olanzapine mediate metabolic abnormalities through different molecular pathways
title_fullStr Haloperidol and olanzapine mediate metabolic abnormalities through different molecular pathways
title_full_unstemmed Haloperidol and olanzapine mediate metabolic abnormalities through different molecular pathways
title_short Haloperidol and olanzapine mediate metabolic abnormalities through different molecular pathways
title_sort haloperidol and olanzapine mediate metabolic abnormalities through different molecular pathways
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3566719/
https://www.ncbi.nlm.nih.gov/pubmed/23321805
http://dx.doi.org/10.1038/tp.2012.138
work_keys_str_mv AT mondelliv haloperidolandolanzapinemediatemetabolicabnormalitiesthroughdifferentmolecularpathways
AT anackerc haloperidolandolanzapinemediatemetabolicabnormalitiesthroughdifferentmolecularpathways
AT vernonac haloperidolandolanzapinemediatemetabolicabnormalitiesthroughdifferentmolecularpathways
AT cattaneoa haloperidolandolanzapinemediatemetabolicabnormalitiesthroughdifferentmolecularpathways
AT natesans haloperidolandolanzapinemediatemetabolicabnormalitiesthroughdifferentmolecularpathways
AT modom haloperidolandolanzapinemediatemetabolicabnormalitiesthroughdifferentmolecularpathways
AT dazzanp haloperidolandolanzapinemediatemetabolicabnormalitiesthroughdifferentmolecularpathways
AT kapurs haloperidolandolanzapinemediatemetabolicabnormalitiesthroughdifferentmolecularpathways
AT pariantecm haloperidolandolanzapinemediatemetabolicabnormalitiesthroughdifferentmolecularpathways